Management's Discussion & Analysis — Q3 2024
Filed Nov 14, 2024 · 22 pages · MD&A
Document
Halcyon Capital Acquisition Corp.
- Filer ID
- 00058812
- Period ended
- September 30, 2024
- Date filed
- November 14, 2024
- Principal regulator
- British Columbia Securities Commission
1. Date
This MD&A is dated November 14, 2024 and should be read in conjunction with the unaudited condensed interim financial statements for the three and nine months ended September 30, 2024.
2. Cautionary Note Regarding Forward-Looking Information
Certain statements in this document constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information reflects current expectations regarding future events and operating performance and speaks only as of the date of this document. Actual results may differ materially. Material factors and assumptions used to develop the forward-looking information and the material risk factors that could cause actual results to differ are described in the Company's most recent Annual Information Form and MD&A. The Company undertakes no obligation to update forward-looking information except as required by applicable securities laws.
3. Overall Performance
The Company continues to evaluate qualifying transaction opportunities. During the quarter, the Company advanced $1,200,000 to Northpeak Lithium Corp. (TSXV: NPLI), a related party by virtue of shared directorship.
5. Liquidity and Capital Resources
As at September 30, 2024 the Company held escrowed IPO proceeds of $8,880,000 in trust. The advance to Northpeak was funded from working capital held outside the escrow account.
Flags raised
Metadata
- SEDAR+ ID
- SP-2024-11-14-HCA-MDA-30144
- Type
- MD&A
- Filed
- Nov 14, 2024
- Period end
- Sep 30, 2024
- Pages
- 22